• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    3/18/26 4:53:07 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDT alert in real time by email
    false 0001896212 0001896212 2026-03-17 2026-03-17 0001896212 CDT:CommonStock0.0001ParValuePerShareMember 2026-03-17 2026-03-17 0001896212 CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-03-17 2026-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 17, 2026

     

    CDT Equity Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41245   87-3272543
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    4581 Tamiami Trail North, Suite 200

    Naples, FL

      34103
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (646) 491-9132

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   CDT   The Nasdaq Stock Market LLC
    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock   CDTTW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On March 17, 2026, CDT Equity Inc. (the “Company”) convened a special meeting of stockholders (the “Special Meeting”). Proxies had been submitted by stockholders representing over one-third of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) outstanding and entitled to vote, which constituted a quorum. At the Special Meeting, the Company’s stockholders voted on seven proposals, which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 6, 2026 (the “Proxy Statement”) and is incorporated herein by reference.

     

    The following is a brief description of the matters voted upon and the results, including the number of votes cast for and against each respective matter and the number of abstentions with respect to each matter. Proxies for the Special Meeting were solicited pursuant to Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and there was no solicitation in opposition of management’s solicitation.

     

    Proposal No. 1. Stockholders approved the issuance of up to 3,685,815 shares of the Company’s Common Stock issuable upon the exercise of certain pre-funded warrants to purchase the Company’s Common Stock in accordance with Nasdaq Listing Rule 5635. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,231,826   79,366   1,184

     

    Proposal No. 2. Stockholders approved the issuance of shares of Common Stock, for purposes of Nasdaq Listing Rule 5635, pursuant to that certain purchase agreement, dated January 16, 2026, establishing an equity line of credit. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,237,240   73,938   1,198

     

    Proposal No. 3. Stockholders approved the issuance of up to 109,978,918 shares of the Company’s Common Stock issuable upon the exercise of certain pre-funded warrants to purchase the Company’s Common Stock in accordance with Nasdaq Listing Rule 5635. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,234,348   76,855   1,173

     

    Proposal No. 4. Stockholders approved one or more amendments of the Company’s Second Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of the Company’s Common Stock, at a ratio ranging from any whole number between and including 1-for-2 and 1-for-100 and in the aggregate not more than 1-for-250, inclusive, as determined by the Company’s board of directors in its discretion, subject to the authority of the board of directors to abandon such amendments. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,238,772   73,473   131

     

    Proposal No. 5. Stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Company from 250,000,000 to 500,000,000 shares. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,233,957   77,247   1,172

     

    Proposal No. 6. Stockholders approved (A) the redomestication of the Company from the State of Delaware to the Cayman Islands by conversion under Delaware law and (B)(i) the redomestication of the Company from the State of Delaware to the Cayman Islands by a transfer by way of continuation under the laws of the Cayman Islands and (ii) the adoption of the memorandum and articles of association of the Company, substantially in the form attached as Annex E to the Company’s Proxy Statement (the “Articles”). The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,217,954   72,557   21,865

     

    Proposal No. 7. Stockholders approved the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2, 3, 4, 5, and 6. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions
    2,216,210   74,447   21,719

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 18, 2026 CDT EQUITY INC.
         
      By: /s/ Andrew Regan
      Name: Andrew Regan
      Title: Chief Executive Officer

     

     

     

     

    Get the next $CDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDT
    SEC Filings

    View All

    CDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/18/26 4:53:07 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/9/26 4:05:49 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by CDT Equity Inc.

    DEF 14A - CDT Equity Inc. (0001896212) (Filer)

    3/6/26 4:12:21 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders. "Following the successful passing of all the proposals at yesterday's Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million," said Dr. Andrew Regan, Chief Executive Officer. "Utilizing cutting edge AI and an

    3/18/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg announced that it has curated a database containing approximately 1,700 rare disease signatures, building upon its existing disease signature library of more than 1,600 conditions, as well as its agrochemical and bacterial signature datasets previously announced. According to Sarborg, structuring rare diseases as machine-interpretable biological signatures enables rapid an

    3/12/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement issued by Sarborg Limited ("Sarborg") regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent. CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg's intellectual property position. Sarborg announced that a provisional patent application was filed with the United States Patent and Trademark Office on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801. The application re

    3/5/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farley Chele Chiavacci was granted 10,553 shares, increasing direct ownership by 160% to 17,157 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    2/23/26 8:27:01 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 224,800 shares (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    12/22/25 4:05:28 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Regan Andrew was granted 1,120,000 shares, increasing direct ownership by 2,545,455% to 1,120,044 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    9/22/25 4:29:05 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Conduit Pharmaceuticals Inc.

    SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/11/24 6:01:23 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide

    3/19/24 7:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Financials

    Live finance-specific insights

    View All

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

    Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP

    7/7/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care